These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 24315504)
41. Injection drug network characteristics as a predictor of injection behaviour. Spelman T; Sacks-Davis R; Dietze P; Higgs P; Hellard M Epidemiol Infect; 2019 Jan; 147():e173. PubMed ID: 31063105 [TBL] [Abstract][Full Text] [Related]
42. Change in injecting behaviour among people treated for hepatitis C virus: The role of intimate partnerships. Malaguti A; Sani F; Stephens BP; Ahmad F; Dugard P; Dillon JF; J Viral Hepat; 2019 Jan; 26(1):65-72. PubMed ID: 30260560 [TBL] [Abstract][Full Text] [Related]
43. Staying safe from hepatitis C: engaging with multiple priorities. Harris M; Treloar C; Maher L Qual Health Res; 2012 Jan; 22(1):31-42. PubMed ID: 21873284 [TBL] [Abstract][Full Text] [Related]
44. Hepatitis B virus exposure and vaccination in a cohort of people who inject drugs: what has been the impact of targeted free vaccination? Winter RJ; Dietze PM; Gouillou M; Hellard ME; Robinson P; Aitken CK J Gastroenterol Hepatol; 2013 Feb; 28(2):314-22. PubMed ID: 23190264 [TBL] [Abstract][Full Text] [Related]
45. Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in San Francisco, CA. Morris MD; Evans J; Montgomery M; Yu M; Briceno A; Page K; Hahn JA PLoS One; 2014; 9(10):e109282. PubMed ID: 25286346 [TBL] [Abstract][Full Text] [Related]
46. Hepatitis C Testing, Status and Treatment among Marginalized People Who Use Drugs in an Inner City Setting: An Observational Cohort Study. Boucher LM; Bayoumi AM; Mark AE; Cooper C; Martin A; Marshall Z; Boyd R; Oickle P; Diliso N; Pineau D; Renaud B; LeBlanc S; Tyndall M; Lee OM; Kendall CE Subst Use Misuse; 2019; 54(1):18-30. PubMed ID: 29932800 [TBL] [Abstract][Full Text] [Related]
47. Needle sharing in regular sexual relationships: an examination of serodiscordance, drug using practices, and the gendered character of injecting. Bryant J; Brener L; Hull P; Treloar C Drug Alcohol Depend; 2010 Mar; 107(2-3):182-7. PubMed ID: 19942380 [TBL] [Abstract][Full Text] [Related]
48. Values and preferences for hepatitis C self-testing among people who inject drugs in Kyrgyzstan. Martínez-Pérez GZ; Nikitin DS; Bessonova A; Fajardo E; Bessonov S; Shilton S BMC Infect Dis; 2021 Jun; 21(1):609. PubMed ID: 34171990 [TBL] [Abstract][Full Text] [Related]
49. High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention. Puzhko S; Roy É; Jutras-Aswad D; Artenie AA; Fortier E; Zang G; Bruneau J Int J Drug Policy; 2017 Sep; 47():61-68. PubMed ID: 28666636 [TBL] [Abstract][Full Text] [Related]
50. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia. Vicknasingam B; Narayanan S; Navaratnam V Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801 [TBL] [Abstract][Full Text] [Related]
51. Injecting drug users' understanding of hepatitis C. O'Brien S; Day C; Black E; Dolan K Addict Behav; 2008 Dec; 33(12):1602-5. PubMed ID: 18762384 [TBL] [Abstract][Full Text] [Related]
52. A qualitative study trialling the acceptability of new hepatitis C prevention messages for people who inject drugs: symbiotic messages, pleasure and conditional interpretations. Treloar C; Newland J; Maher L Harm Reduct J; 2015 Mar; 12():5. PubMed ID: 25884357 [TBL] [Abstract][Full Text] [Related]
53. HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco. Page K; Evans JL; Hahn JA; Vickerman P; Shiboski S; Morris MD PLoS One; 2019; 14(12):e0226166. PubMed ID: 31821365 [TBL] [Abstract][Full Text] [Related]
54. Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia. Butler K; Day C; Sutherland R; van Buskirk J; Breen C; Burns L; Larney S Int J Drug Policy; 2017 Sep; 47():102-106. PubMed ID: 28789820 [TBL] [Abstract][Full Text] [Related]
55. Modelling hepatitis C transmission over a social network of injecting drug users. Rolls DA; Daraganova G; Sacks-Davis R; Hellard M; Jenkinson R; McBryde E; Pattison PE; Robins GL J Theor Biol; 2012 Mar; 297():73-87. PubMed ID: 22185979 [TBL] [Abstract][Full Text] [Related]
56. Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs. Treloar C; Hull P; Bryant J; Hopwood M; Grebely J; Lavis Y Drug Alcohol Depend; 2011 Jul; 116(1-3):52-6. PubMed ID: 21194852 [TBL] [Abstract][Full Text] [Related]
57. 'Beyond the willing & the waiting' - The role of peer-based approaches in hepatitis C diagnosis & treatment. Henderson C; Madden A; Kelsall J Int J Drug Policy; 2017 Dec; 50():111-115. PubMed ID: 28927831 [TBL] [Abstract][Full Text] [Related]
58. Drug network identification predicts injecting risk behavior among people who inject drugs on hepatitis C virus treatment in Tayside, Scotland. Malaguti A; Byrne CJ; Sani F; Power K; Eriksen A; Dillon JF Behav Med; 2024; 50(2):130-140. PubMed ID: 36411523 [TBL] [Abstract][Full Text] [Related]
59. At the intersection of marginalised identities: lesbian, gay, bisexual and transgender people's experiences of injecting drug use and hepatitis C seroconversion. Deacon RM; Mooney-Somers J; Treloar C; Maher L Health Soc Care Community; 2013 Jul; 21(4):402-10. PubMed ID: 23465052 [TBL] [Abstract][Full Text] [Related]
60. Low rates of hepatitis C testing among people who inject drugs in Thailand: implications for peer-based interventions. Ti L; Kaplan K; Hayashi K; Suwannawong P; Wood E; Kerr T J Public Health (Oxf); 2013 Dec; 35(4):578-84. PubMed ID: 23335599 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]